Olmesartan Medoxomil and Amlodipine Tablet

OLMEROOT-AM 40/5

Olmesartan Medoxomil 40 mg and Amlodipine 5 mg Tablets

Division: DIABGLYM

Composition

Each tablet contains:

Olmesartan Medoxomil IP — 40 mg

Amlodipine IP — 5 mg

Excipients — q.s.

Colour: Approved colour used

Dosage form: Oral tablet

Product Description

OLMEROOT-AM 40/5 is a scientifically balanced antihypertensive combination of Olmesartan Medoxomil 40 mg and Amlodipine 5 mg, formulated for the effective management of moderate to severe hypertension and long-term cardiovascular risk reduction. This combination provides dual blood pressure control by combining the renin-angiotensin system blockade of Olmesartan with the sustained vasodilatory action of Amlodipine, resulting in superior antihypertensive efficacy and enhanced target organ protection.

Olmesartan Medoxomil is a potent angiotensin II receptor blocker (ARB) that promotes vasodilation, reduces peripheral vascular resistance, and provides cardiovascular and renal protection. Amlodipine is a long-acting calcium channel blocker that relaxes vascular smooth muscle, improves arterial compliance, and provides sustained 24-hour blood pressure control.

OLMEROOT-AM 40/5 is particularly beneficial in patients with uncontrolled hypertension, hypertension associated with diabetes, chronic kidney disease, metabolic syndrome, obesity, elderly hypertension, left ventricular hypertrophy, and patients requiring intensive combination antihypertensive therapy.

Technical Knowledge of Olmesartan Medoxomil and Amlodipine

Olmesartan Medoxomil is a prodrug that is converted to Olmesartan, which selectively blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction, aldosterone secretion, sympathetic activation, and vascular remodeling.

Amlodipine inhibits L-type calcium channels in vascular smooth muscle, producing sustained arterial vasodilation, reducing peripheral vascular resistance, improving vascular compliance, and maintaining stable blood pressure control throughout the dosing interval.

The combination of Olmesartan and Amlodipine provides complementary antihypertensive mechanisms with enhanced cardiovascular and renal protective benefits.

Mechanism of Action

Olmesartan blocks AT1 receptors, promotes vasodilation, reduces peripheral vascular resistance, decreases aldosterone secretion, improves vascular function, and protects cardiovascular and renal tissues.

Amlodipine relaxes vascular smooth muscle, reduces arterial resistance, improves vascular compliance, enhances coronary blood flow, and provides sustained antihypertensive action.

Key Benefits

Effective reduction of systolic and diastolic blood pressure

Dual antihypertensive mechanism

Provides sustained 24-hour blood pressure control

Supports cardiovascular and renal protection

Improves vascular compliance and endothelial function

Reduces peripheral vascular resistance

Effective in diabetic and chronic kidney disease patients

Convenient once-daily dosing

Suitable for long-term hypertension management under medical supervision

Clinical Applications

OLMEROOT-AM 40/5 is commonly prescribed for moderate to severe hypertension, uncontrolled hypertension requiring combination therapy, hypertension with diabetes mellitus, hypertension with chronic kidney disease, hypertension with metabolic syndrome, elderly hypertension, left ventricular hypertrophy, and long-term cardiovascular risk reduction.

Facts About Olmesartan Medoxomil and Amlodipine

Olmesartan is a highly selective ARB with excellent antihypertensive efficacy and proven cardiovascular and renal protective benefits. Amlodipine is one of the most extensively prescribed calcium channel blockers worldwide and provides effective long-term blood pressure control. The combination is widely recommended for patients requiring dual antihypertensive therapy because of its excellent efficacy, tolerability, and target organ protective effects.

Key Facts

ARB and calcium channel blocker combination therapy

Olmesartan Medoxomil 40 mg for intensive vascular and renal protection

Amlodipine 5 mg for sustained arterial vasodilation

Provides 24-hour comprehensive blood pressure control

Effective in moderate to severe hypertension

Evidence-based cardiovascular combination therapy

Quality-assured pharmaceutical formulation

PCD Pharma Franchise Opportunity

OLMEROOT-AM 40/5 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, chronic kidney disease, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this combination.

Why Choose OLMEROOT-AM 40/5 for PCD Pharma Franchise?

High prescription potential

Strong physician and cardiologist acceptance

Attractive monopoly franchise opportunity

Competitive pricing

Promotional support available

Visual aids and marketing inputs

Consistent product quality

Excellent repeat business potential

Third Party Manufacturing

Chemsroot Pharmaceutical offers Third Party Manufacturing of Olmesartan Medoxomil 40 mg and Amlodipine 5 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.

Our Third Party Manufacturing Services Include

Private label manufacturing

Contract manufacturing

Custom brand manufacturing

Loan license manufacturing

DCGI-compliant production

GMP-certified manufacturing

Batch manufacturing documentation

Product registration support

Customized packaging and artwork

Monopoly franchise packaging

Bulk manufacturing capability

Manufacturing Features

Pharmaceutical-grade raw materials

IP/BP/USP quality standards

In-process quality control

Finished product testing

Stability-oriented formulation

Moisture-controlled tablet manufacturing

Blister and Alu-Alu packaging options

OLMEROOT-AM 40/5 from DIABGLYM combines effective blood pressure control, comprehensive cardiovascular and renal protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Olmesartan and Amlodipine formulation.